君实生物 · Junshi Biosciences

Science

R&D Overview

Our research spans four therapeutic areas. Teams in China and the United States contribute to discovery and the development of medicines for patients.

Our innovation platform

Research at Junshi Biosciences

Therapeutic Areas

Oncology

Antibodies, antibody-drug conjugates and small molecules in solid tumors and hematologic malignancies.

See programs

Autoimmune

Medicines for immune-mediated conditions, including adalimumab for rheumatoid arthritis.

See programs

Metabolic

Research in lipid disorders, including ongericimab, an antibody targeting PCSK9.

See programs

Infectious diseases

Antiviral medicines, including deuremidevir hydrobromide (VV116) for COVID-19.

See programs

Research Platforms & Modalities

Junshi’s platforms connect antibody discovery with development and industrial scale-up. Innovation centers in Shanghai and Suzhou support the process from target discovery through clinical development.

Antibodies

Monoclonal, bispecific and multispecific antibodies are represented in Junshi’s research portfolio.

Antibody-drug conjugates

Junshi is advancing antibody-drug conjugates, including JS212 for selected solid tumors.

Additional modalities

Other research programs include small molecules, fusion proteins and nucleic acid medicines.

Explore the company’s R&D pipeline

Explore Our Research

Clinical trials

Find company-sponsored studies and check registry information.

Find a trial